OraSure Technologies is a point-of-need diagnostics company whose second-quarter GAAP profit is the wrong headline. The swing to black ink came from writing down a Sherlock Biosciences earnout after the company pulled its InteliQuick chlamydia and gonorrhea self-test from Food and Drug Administration review. That accounting credit is the inverse of the operating story. The product that was supposed to reopen growth in the United States is now delayed past this year.
Sequential revenue of $31 million cleared the company's own range and rose from the first quarter. Core sales excluding leftover COVID testing and the exited risk-assessment line stayed flat versus last year. Gross margin expanded as scrap fell and manufacturing sat inside the Pennsylvania plants. Strip out the $23 million contingent-consideration credit and the non-GAAP operating loss widened versus a year ago. Cash ended the quarter at $161 million, down from year-end after buybacks and operating use. The franchise is no longer shrinking as fast as it did through last year, but it is not yet funding itself.
Two real regulatory wins landed beside the Sherlock setback. The agency cleared Colli-Pee Dx for at-home urine collection on Roche sexually transmitted infection assays, and it granted emergency use authorization for a second-generation OraQuick Ebola antigen test. Management paused the repurchase program to keep powder dry for those launches and is pointing to cash-flow break-even as next year begins. The debate is whether a cash-rich stub trading below book is cheap insurance on a stabilizing franchise, or a value trap waiting on public-health budgets and a resubmitted molecular test. Does Colli-Pee plus syphilis and Sickle SCAN produce enough growth to stop the cash bleed without Sherlock?